Patent ID: 11866449
Assignee: NSC THERAPEUTICS GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 1:
2. The method of claim 1, wherein
(a) the X-ray powder diffraction pattern contains at least two, three or all of the following 2-theta values as measured using CuKα radiation: 8.8, 12.30, 17.30, 17.50, 17.80 and 23.0;
(b) the X-ray powder diffraction pattern also contains at least one of the following 2-theta values as measured using CuKα radiation: 12.3, 19.9, 21.6, 24.5, 26.3 and 31.6;
(c) the X-ray powder diffraction pattern is substantially free of peaks having 2-theta values in the range of from 10.8-11.8;
(d) the X-ray powder diffraction pattern contains at least one of the following 2-theta values as measured using CuKα radiation: 12.2, 17.3, 19.9, 21.6, 24.5, 26.3 and 31.6, and wherein said X-ray powder diffraction is substantially free of peaks having 2-theta values in the range of from 10.8-11.8;
(e) the X-ray powder diffraction pattern contains at least two, three, four, five or all of the following 2-theta values as measured using CuKα radiation 12.2, 17.3, 17.5, 19.9, 21.6, 24.5, 26.3 and 31.2;
the 13C solid-state NMR of the crystalline form contains resonances having at least two, three, four or all of the following chemical shift values as expressed in ppm relative to TMS: 67.56, 54.60, 41.49, 30.70 and 13.77;
(g) the 13C solid-state NMR of the crystalline form contains at least two, three, four or all differences in chemical shift between the resonance having the largest chemical shift and other resonances selected from 107.3, 120.3, 133.4, 144.2 and 161.1; or
(h) the ZnSe ATR-FT-IR absorption spectrum of the crystalline form contains at least two, three, four, five, six or all absorption peaks having a value selected from 1039, 1353, 1369, 1388, 2918, 2974 and 3088 cm−1.